IRF3 and neoplasm: Fumarate can directly bind to and inhibit the activity of the STING protein, blocking the cGAMP-mediated STING-IRF3 signal transduction, leading to a decrease in the secretion of type I interferons, thereby weakening the anti-tumor immune response and causing drug resistance to immune therapies (48).